Theralase Technologies Inc (TLTFF)

[123414]

Theralase Researchers Receive Government Grant



Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical-stage pharmaceutical company dedicated to the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations used to safely and effectively destroy cancer is pleased to announce that Theralase researchers; specifically: University Health Network (“UHN”) and the University of Toronto (“UT”) have received an Ontario Research Fund – Research Excellence (“ORF-RE”) grant with a primary mandate of advancing personalized Anti-Cancer Photo Dynamic Therapy (“PDT”) for each individual cancer patient to safely and effectively destroy their particular cancer, while maintaining the highest possible quality of life for them.



UHN and UT were successfully awarded an ORF-RE grant valued at $CAN 4.5 million, with financial and technical support provided by world-class industrial and institutional partners, such as: IBM Canada, Altera (Intel), Theralase and Companion Healthcare Corporation (“CHC”), further supported with funding from the Ontario government’s Ministry of Research and Innovation and Science.